Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $211.72, giving the company a market capitalization of 518.6B. It carries a P/E multiple of 20.42 and pays a dividend yield of 2.4%.
On 2025-12-14, Johnson & Johnson(JNJ) stock moved within a range of $208.96 to $212.27. With shares now at $211.72, the stock is trading +1.3% above its intraday low and -0.3% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 6.92M, versus its average volume of 8.49M.
The stock's 52-week range extends from a low of $140.68 to a high of $212.27.
The stock's 52-week range extends from a low of $140.68 to a high of $212.27.
JNJ News
If you are wondering whether Johnson & Johnson is still a buy after its big run, you are not alone. This article is going to focus squarely on what the current...
Johnson & Johnson announced the U.S. Food and Drug Administration, FDA, approved the supplemental New Drug Application, sNDA, for AKEEGA plus prednisone for the...
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for AKEEGA—a...
Analyst ratings
59%
of 27 ratingsMore JNJ News
The Food and Drug Administration said it approved Akeega with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castratio...
Key Points A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year de...
Johnson & Johnson has recently reported Phase 3 data showing that TECVAYLI plus DARZALEX FASPRO cut the risk of disease progression or death versus standard reg...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
RBC Capital raised the firm’s price target on Johnson & Johnson to $230 from $209 and keeps an Outperform rating on the shares after hosting an investor visit t...
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blu...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $190.00. TipRanks Cyber Monday Sale Claim...